Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.
Get in now, because in a couple months this is gonna be out of reach.
More
Bio Stocks™ Retweeted Bio Stocks™
$SMMT Ezutromid Development to be Discontinued.Bio Stocks™ added,
Roadman Investments Investee Champignon Brands to Develop Mushroom-infused Cold Brew Coffee in Collaboration With Drip Coffee Social Ltd.
In late September, RMANF announced that the Company’s investee Champignon Brands Inc. (“Champignon”) has entered into a Product Formulation and R&D Agreement (the “Agreement”) with Nanaimo, B.C. based Drip Coffee Social Ltd. (“Drip Coffee”).
https://www.tradingview.com/chart/RMANF/aVxRVylL-RMANF-New-Cannabis-Alternative-Jumps-21-during-Mondays-session/
If this drug is then made available for 100% of DMD boys and mrkt cap is say $2 billion ... investment of $100 would be X 10 by year end = $1000.
IMO the only risk folk are taking here is the very remote possibility that EZD 24 wk data was some fluke. (So there is a small risk still attached) We know the trial has been completed and NO safety issues. Just slight improvement in figures (continued build up off drug most likely to show improvement) will most likely result in a pass for qMR endpoint and in response the 6MWT and ambulatory functions will show actual positive effect. (Though as in Sarepta's case this was only shown to be tiny improvement at end of P2 ... not IMO relying on those figures which have historically been hard to show elsewhere)
We also know that this drug will in principle help Becker MD sufferers ... that's the same number of sufferers again. Summit will also carry on increasing in value as C Diff and Gonorrhea drugs complete trials. C Diff has already passed P2 and shown to be very best in class .... keeping thousands of people alive who simply go into hospitals and pick up C Diff whilst undergoing routine operations. C Diff P3 trials 2019. Over the next few years millions will die from this without help.
If I were to recommend someone investing $100 where to put it "right here - right now" ... there aren't many companies capable of such reward with this low risk. However ....DYOR.